Comprehensive Stock Comparison
Compare Bicycle Therapeutics plc (BCYC) vs Immunome, Inc. (IMNM) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth | BCYC | 30.8% revenue growth vs IMNM's -35.5% |
| Quality / Margins | BCYC | -8.8% net margin vs IMNM's -23.0% |
| Stability / Safety | BCYC | Beta 1.17 vs IMNM's 1.42, lower leverage |
| Dividends | Tie | Neither pays a meaningful dividend |
| Momentum (1Y) | IMNM | +132.6% vs BCYC's -47.8% |
| Efficiency (ROA) | BCYC | -32.8% ROA vs IMNM's -74.4% |
Who Each Stock Is For
Income & stability
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Defensive / Recession hedge
Business Model
What each company does and how it makes money
Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing a novel class of medicines called Bicycles — fully synthetic peptides constrained to form two loops — for cancer and other diseases. It generates revenue primarily through research collaborations and licensing deals with larger pharmaceutical partners, while advancing its own pipeline of oncology candidates through clinical trials. The company's key advantage is its proprietary Bicycle platform technology, which creates small-molecule-like drugs with antibody-like specificity — potentially offering better tumor penetration than traditional biologics.
Immunome is a biopharmaceutical company that discovers and develops antibody therapeutics for cancer and infectious diseases. It generates revenue primarily through research collaborations and licensing agreements — with no commercial products yet — as it advances its pipeline of antibody candidates. The company's key advantage lies in its proprietary discovery platform that identifies human antibodies from patient immune responses, potentially yielding more effective and safer therapeutic candidates.
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
BCYC leads in 3 of 6 categories (Financial Metrics, Valuation Metrics). IMNM leads in 1 (Total Returns). 1 tied.
Financial Metrics (TTM)
BCYC is the larger business by revenue, generating $28M annually — 2.9x IMNM's $10M. BCYC is the more profitable business, keeping -8.8% of every revenue dollar as net income compared to IMNM's -23.0%. On growth, BCYC holds the edge at +3.4% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | BCYCBicycle Therapeut… | IMNMImmunome, Inc. |
|---|---|---|
| RevenueTrailing 12 months | $28M | $10M |
| EBITDAEarnings before interest/tax | -$293M | -$232M |
| Net IncomeAfter-tax profit | -$251M | -$223M |
| Free Cash FlowCash after capex | -$242M | -$192M |
| Gross MarginGross profit ÷ Revenue | -5.5% | -4.2% |
| Operating MarginEBIT ÷ Revenue | -10.2% | -24.2% |
| Net MarginNet income ÷ Revenue | -8.8% | -23.0% |
| FCF MarginFCF ÷ Revenue | -8.5% | -19.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | +3.4% | -100.0% |
| EPS Growth (YoY)Latest quarter vs prior year | -14.9% | +16.7% |
Valuation Metrics
| Metric | BCYCBicycle Therapeut… | IMNMImmunome, Inc. |
|---|---|---|
| Market CapShares × price | $111M | $2.0B |
| Enterprise ValueMkt cap + debt − cash | -$759M | $1.9B |
| Trailing P/EPrice ÷ TTM EPS | -1.98x | -4.37x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 3.16x | 221.74x |
| Price / BookPrice ÷ Book value/share | 0.42x | 7.08x |
| Price / FCFMarket cap ÷ FCF | — | — |
Profitability & Efficiency
BCYC delivers a -40.5% return on equity — every $100 of shareholder capital generates $-41 in annual profit, vs $-84 for IMNM. BCYC carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to IMNM's 0.03x. On the Piotroski fundamental quality scale (0–9), BCYC scores 5/9 vs IMNM's 1/9, reflecting solid financial health.
| Metric | BCYCBicycle Therapeut… | IMNMImmunome, Inc. |
|---|---|---|
| ROE (TTM)Return on equity | -40.5% | -84.4% |
| ROA (TTM)Return on assets | -32.8% | -74.4% |
| ROICReturn on invested capital | — | -7.0% |
| ROCEReturn on capital employed | -29.7% | -195.6% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 1 |
| Debt / EquityFinancial leverage | 0.01x | 0.03x |
| Net DebtTotal debt minus cash | -$870M | -$139M |
| Cash & Equiv.Liquid assets | $880M | $143M |
| Total DebtShort + long-term debt | $9M | $5M |
| Interest CoverageEBIT ÷ Interest expense | -1331.02x | — |
Total Returns (with DRIP)
A $10,000 investment in IMNM five years ago would be worth $5,472 today (with dividends reinvested), compared to $2,232 for BCYC. Over the past 12 months, IMNM leads with a +132.6% total return vs BCYC's -47.8%. The 3-year compound annual growth rate (CAGR) favors IMNM at 68.5% vs BCYC's -36.8% — a key indicator of consistent wealth creation.
| Metric | BCYCBicycle Therapeut… | IMNMImmunome, Inc. |
|---|---|---|
| YTD ReturnYear-to-date | -14.2% | +5.0% |
| 1-Year ReturnPast 12 months | -47.8% | +132.6% |
| 3-Year ReturnCumulative with dividends | -74.8% | +378.3% |
| 5-Year ReturnCumulative with dividends | -77.7% | -45.3% |
| 10-Year ReturnCumulative with dividends | -52.2% | +62.5% |
| CAGR (3Y)Annualised 3-year return | -36.8% | +68.5% |
Risk & Volatility
BCYC is the less volatile stock with a 1.17 beta — it tends to amplify market swings less than IMNM's 1.42 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. IMNM currently trades 79.1% from its 52-week high vs BCYC's 51.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | BCYCBicycle Therapeut… | IMNMImmunome, Inc. |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.17x | 1.42x |
| 52-Week HighHighest price in past year | $11.16 | $27.65 |
| 52-Week LowLowest price in past year | $5.18 | $5.15 |
| % of 52W HighCurrent price vs 52-week peak | +51.3% | +79.1% |
| RSI (14)Momentum oscillator 0–100 | 44.1 | 42.9 |
| Avg Volume (50D)Average daily shares traded | 264K | 1.5M |
Analyst Outlook
Wall Street rates BCYC as "Buy" and IMNM as "Buy". Consensus price targets imply 92.0% upside for BCYC (target: $11) vs 61.4% for IMNM (target: $35).
| Metric | BCYCBicycle Therapeut… | IMNMImmunome, Inc. |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $11.00 | $35.29 |
| # AnalystsCovering analysts | 21 | 9 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Nov 20 | Feb 26 | Change |
|---|---|---|---|
| Bicycle Therapeutic… (BCYC) | 100 | 35.46 | -64.5% |
| Immunome, Inc. (IMNM) | 81.64 | 194.35 | +138.1% |
Immunome, Inc. (IMNM) returned -45% over 5 years vs Bicycle Therapeutic… (BCYC)'s -78%.
Chart 2Revenue Growth — 10 Years
| Stock | 2016 | 2024 | Change |
|---|---|---|---|
| Bicycle Therapeutic… (BCYC) | $0.00 | $35M | — |
| Immunome, Inc. (IMNM) | $0.00 | $9M | — |
Bicycle Therapeutics plc's revenue grew from $0M (2016) to $35M (2024) — a 0.0% CAGR.
Chart 3Net Margin Trend — 10 Years
| Stock | 2017 | 2024 | Change |
|---|---|---|---|
| Bicycle Therapeutic… (BCYC) | -7.9% | -4.8% | +39.3% |
| Immunome, Inc. (IMNM) | -7.6% | -32.4% | -325.3% |
Bicycle Therapeutics plc's net margin went from -8% (2017) to -5% (2024).
Chart 4EPS Growth — 10 Years
| Stock | 2016 | 2024 | Change |
|---|---|---|---|
| Bicycle Therapeutic… (BCYC) | -0.76 | -2.9 | -281.6% |
| Immunome, Inc. (IMNM) | -7.18 | -5 | +30.4% |
Bicycle Therapeutics plc's EPS grew from $-0.76 (2016) to $-2.90 (2024).
Chart 5Free Cash Flow — 5 Years
Bicycle Therapeutics plc generated $-166M FCF in 2024 (-886% vs 2021). Immunome, Inc. generated $-164M FCF in 2024 (-798% vs 2021).
BCYC vs IMNM: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Is BCYC or IMNM a better buy right now?
Analysts rate Bicycle Therapeutics plc (BCYC) a "Buy" — based on 21 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — BCYC or IMNM?
Over the past 5 years, Immunome, Inc. (IMNM) delivered a total return of -45.3%, compared to -77.7% for Bicycle Therapeutics plc (BCYC). A $10,000 investment in IMNM five years ago would be worth approximately $5K today (assuming dividends reinvested). Over 10 years, the gap is even starker: IMNM returned +62.5% versus BCYC's -52.2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — BCYC or IMNM?
By beta (market sensitivity over 5 years), Bicycle Therapeutics plc (BCYC) is the lower-risk stock at 1.17β versus Immunome, Inc.'s 1.42β — meaning IMNM is approximately 21% more volatile than BCYC relative to the S&P 500. On balance sheet safety, Bicycle Therapeutics plc (BCYC) carries a lower debt/equity ratio of 1% versus 3% for Immunome, Inc. — giving it more financial flexibility in a downturn.
04Which has better profit margins — BCYC or IMNM?
Bicycle Therapeutics plc (BCYC) is the more profitable company, earning -479.2% net margin versus -32.4% for Immunome, Inc. — meaning it keeps -479.2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BCYC leads at -595.0% versus -33.8% for IMNM. At the gross margin level — before operating expenses — IMNM leads at 100.0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — BCYC or IMNM?
None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.
06Is BCYC or IMNM better for a retirement portfolio?
For long-horizon retirement investors, Bicycle Therapeutics plc (BCYC) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.17)). Both have compounded well over 10 years (BCYC: -52.2%, IMNM: +62.5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between BCYC and IMNM?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.